Baseline immunity predicts prognosis of pancreatic cancer patients treated with WT1 and/or MUC1 peptide-loaded dendritic cell vaccination and a standard chemotherapy

References

• Siegel R, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. doi:10.3322/caac.21654.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegal R, Torre L, Jemal A. Global cancer statistics 2018: BLOBOCAN estimates of incidence and mortality worldwide for 36 cancers. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492.
   PubMed Web of Science ®Google Scholar
• Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet. 2020;395(10242):2008–20. doi:10.1016/S0140-6736(20)30974-0.
   PubMed Web of Science ®Google Scholar
• Chiorean EG, Cheung WY, Giordano G, KimG, Al-Batran SE. Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review. Ther Adv Med Oncol. 2019;11:1–17. doi:10.1177/1758835919850367.
   Web of Science ®Google Scholar
• Wainberg ZA, Hochster HS, Kim EJ, George B, Kaylan A, ChioreanEG, Waterhouse DM, Guiterrez M, Parikh A, Jain R, et al. Open-label, phase I study of nivolumab combined with nab-paclitaxel plus gemcitabine in advanced pancreatic cancer. Clin Cancer Res. 2020;26(18):4814–22. doi:10.1158/1078-0432.CCR-20-0099.
   PubMed Web of Science ®Google Scholar
• Wu AA, Bever KM, Ho WJ, Fertig EJ, Niu N, Zheng L, Parkinson RM, Durham JN, Onners B, Ferguson AK, et al. A Phase II study of allogeneic GM-CSF-transfected pancreatic tumor vaccine (GVAX) with ipilimumab as maintenance treatment for metastatic pancreatic cancer. Clin Cancer Res. 2020;26(19):5129–39. doi:10.1158/1078-0432.CCR-20-1025.
   PubMed Web of Science ®Google Scholar
• Bancherereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392(6673):245–52. doi:10.1038/32588.
   PubMed Web of Science ®Google Scholar
• Amedei A, Niccolai E, Prisco D. Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy. Hum Vaccin Immunother. 2014;10(11):3354–68. doi:10.4161/hv.34392.
   PubMed Web of Science ®Google Scholar
• Oji Y, Nakamori S, Fujikawa M, Nakatsuka S, Yokota A, Tatsumi N, Abeno S, Ikeba A, TakashimaS, Tsujie M, et al. Overexpression of the Wilms’ tumor gene WT1 in pancreatic ductal adenocarcinoma. Cancer Sci. 2004;95(7):583–87. doi:10.1111/j.1349-7006.2004.tb02490.x.
   PubMed Web of Science ®Google Scholar
• Hinoda Y, Ikematsu Y, Horinochi M, SatoS, YamamotoK, Nakano T, Fukui M, Suehiro Y, Hamanaka Y, Nishikawa Y, et al. Increased expression of MUC1 in advanced pancreatic cancer. JGastroenterol. 2003;38(12):1162–66. doi:10.1007/s00535-003-1224-6.
   PubMed Web of Science ®Google Scholar
• Scharnhost V, van der Eb AJ, Jochemsen AG. WT1 proteins: functions in growth and differentiation. Gene. 2001;273(2):141–61. doi:10.1016/s0378-1119(01)00593-5.
   PubMed Web of Science ®Google Scholar
• Nakatsuka S, OjiY, Horiuchi T, Kanda T, Kitagawa M, Takeuchi T, Kawano K, Kuwae Y, Yamauchi A, Okumura M, et al. Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod Pathorol. 2006;19(6):804–14. doi:10.1038/modpathol.3800588.
   PubMed Web of Science ®Google Scholar
• Gendler SJ, Lancaster CA, Taylor-Papadimitriou J, Duhig T, Peast N, Burchell J, Pemberton L, Lalani EN, Wilson D. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem. 1990;265(25):15286–93. doi:10.1016/S0021-9258(18)77254-2.
   PubMed Web of Science ®Google Scholar
• Masaki Y, OkaM, Ogura Y, Ueno T, Nishihara K, Tangoku A, TakahashiM, Yamamoto M, Irimura T. Sialylated MUC1 mucin expression in normal pancreas, benign pancreatic lesions and pancreatic ductal adenocarcinoma. Hepatogastroenterology. 1999;46:2240–45.
   PubMedGoogle Scholar
• Nishida S, Koid S, Takeda Y, HommaS, KomitaH, Takahara A, Morita S, Ito T, Morimoto S, HaraK, et al. Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer. J Immunother. 2014;37(2):105–14. doi:10.1097/CJI.0000000000000020.
   PubMed Web of Science ®Google Scholar
• Kimura Y, Tsukada J, Tomoda T, Takahashi H, Imai K, Shimamura K, Sunamura M, Yonemitsu Y, ShimodairaS, KoidoS, et al. Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma. Pancreas. 2012;41(2):195–205. doi:10.1097/MPA.0b013e31822398c6.
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Shimodaira S, Nagai K, Ogasawara M, Takahashi H, Abe H, Tanii M, Okamoto M, Tsujitani S, Yusa S, et al. Prognostic factors related to add-on dendritic cell vaccines on patients with inoperable pancreatic cancer receiving chemotherapy: a multicenter analysis. Cancer Immunol Immunother. 2014;63(8):797–806. doi:10.1007/s00262-014-1554-7.
   PubMed Web of Science ®Google Scholar
• Koido S, Homma S, Okamoto M, TakakuraK, Mori M, Yoshizaki S, Tsukinaga S, Odahara S, Koyama S, Imazu H, et al. Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms’ Tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer. Clin Cancer Res. 2014;20(16):4228–39. doi:10.1158/1078-0432.CCR-14-0314.
   PubMed Web of Science ®Google Scholar
• Mayanagi S, Kitago M, Sakurai T, Matsuda T, Fujita T, Higuchi H, Taguchi H, Itano O, Aiura K, Hamamoto Y, et al. Phase I pilot study of Wilms tumor gene 1 peptide-pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer. Cancer Sci. 2015;106(4):397–406. doi:10.1111/cas.12621.
   PubMed Web of Science ®Google Scholar
• Kondo H, Hazama S, Kawaoka T, Yoshino S, Yoshida S, Tokuno K, Takashima M, Ueno T, Hinoda Y, Oka M. Adaptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes. Anticancer Res. 2008;28(1B):379–88. PMID: 18383873.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–703. doi:10.1056/NEJMoa1304369.
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarm Y, Adenis A, Raoul J-L, Gourgou-Bourgade S, de la Fouchardiere C, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25. doi:10.1056/NEJMoa1011923.
   PubMed Web of Science ®Google Scholar
• Takahara A, Koido S, Ito M, Nagasaki E, Sagawa Y, Iwamoto T, Komita H, Ochi T, Fujiwara H, Yasukawa M, et al. Gemcitabine enhances Wilms’ tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-cell-mediated antitumor immune response. Cancer Immunol Immunother. 2011;60(9):1289–97. doi:10.1007/s00262-011-1033-3.
   PubMed Web of Science ®Google Scholar
• Soeda A, Morita-Hoshi Y, Makiyama H, Morizane C, Ueno H, Ikeda M, Okusaka T, Yamagata S, Takahashi N, Hyodo I, et al. Regular dose of gemcitabine induces an increase in CD14+ monocytes and CD11c+ dendritic cells in patients with advanced pancreatic cancer. Jpn J Clin Oncol. 2009;39(12):797–806. doi:10.1093/jjco/hyp112.
   PubMed Web of Science ®Google Scholar
• Lim SH, Chua W, Cheng C, Descallar J, Ng W, Solomon M, Bokey L, Wong K, Lee MT, de Souza P, et al. Effect of neoadjuvant chemoradiation on tumor-infiltrating/associated lymphocytes in locally advanced rectal cancers. Anticancer Res. 2014;34(11):6505–13. PMID: 25368252.
   PubMed Web of Science ®Google Scholar
• Kanterman J, Sade-Feldman M, Biton M, Ish-Shalom E, Lasry A, Goldshtein A, Hubert A, Baniyash M. Adverse immunoregulatory effects of 5FU and CPT11 chemotherapy on myeloid-derived suppressor cells and colorectal cancer outcomes. Cancer Res. 2014;74(21):6022–35. PMID: 25209187. doi:10.1158/0008-5472.CAN-14-0657.
   PubMed Web of Science ®Google Scholar
• Demaria S, Volm MD, Shapiro RL, Yee HT, Oratz R, Formenti SC, Muggia F, Symmans WF. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin Cancer Res. 2001;7(10):3025–30. PMID: 11595690.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Aparicio M, Alzuguren P, Mauleon I, Medina-Echeverz J, Hervas-Stubbs S, Mancheno U, Berraondo P, Crettaz J, Gonzalez-Aseguinolaza G, Prieto J, et al. Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice. Gut. 2011;60(3):341–49. doi:10.1136/gut.2010.211722.
   PubMed Web of Science ®Google Scholar
• Ogasawara M, Miyashita M, Ota S. Vaccination of urological cancer patients with WT1 peptide-pulsed dendritic cells in combination with molecular targeted therapy or conventional chemotherapy induces immunological and clinical responses. Ther Apher Dial. 2018;22(3):266–77. doi:10.1111/1744-9987.12694.
   PubMed Web of Science ®Google Scholar
• Ogasawara M, Miyashita M, YamagishiY, Ota S. Phase I/II pilot study of Wilms’ tumor 1 peptide-pulsed dendritic cell vaccination combined with conventional chemotherapy in patients with head and neck cancer. Ther Apher Dial. 2019;23(3):279–88. doi:10.1111/1744-9987.12831.
   PubMed Web of Science ®Google Scholar
• Ogasawara M, Miyashita M, Yamagishi Y, Ota S. Immunotherapy employing dendritic cell vaccination for patients with advanced or relapsed esophageal cancer. Ther Apher Dial. 2020;24(5):482–91. doi:10.1111/1744-9987.13542.
   PubMed Web of Science ®Google Scholar
• Stotz M, Gerger A, Eisner F, Szkandera J, Loibner H, Ress AL, Kornprat P, AlXoughbi W, Seggewies FS, Lacner C, et al. Increase neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer. 2013;109(2):416–21. doi:10.1038/bjc.2013.332.
   PubMed Web of Science ®Google Scholar
• Imaoka H, Mizuno N, Hara K, Hijioka S, Tajika M, TanakaT, Ishihara M, Yogi T, Tsutsumi H, Fujiyoshi T, et al. Evaluation of modified Glasgow prognostic score for pancreatic cancer: a retrospective cohort study. Pancreas. 2016;45(2):211–17. doi:10.1097/MPA.0000000000000446.
   PubMed Web of Science ®Google Scholar
• Dolan RD, McSorley ST, Horgan PG, Laird B, McMillan DC. The role of the systemic inflammatory response in predicting outcomes in patients with advanced inoperable cancer: systematic review and meta-analysis. Crit Rev Oncol Hematol. 2017;116:134–46. doi:10.1016/j.critrevonc.2017.06.002.
   PubMed Web of Science ®Google Scholar
• Kanai T, Ito Z, Oji Y, Suka M, Nishida S, Takakura K, Kajihara M, Saruta M, Fujioka S, Misawa T, et al. Prognostic significance of Wilms’ tumor 1 expression in patients with pancreatic ductal adenocarcinoma. Oncol Lett. 2018;16(2):2682–92. doi:10.3892/ol.2018.8961.
   PubMed Web of Science ®Google Scholar
• Ryoma Y, MoriyaY, Okamoto M, Kanaya I, Saito M, Sato M. Biological effect of OK-432 (picibanil) and possible application to dendritic cell therapy. Anticancer Res. 2004;24(5C):3295–301. PMID: 15515424.
   PubMed Web of Science ®Google Scholar
• Gochi A, Orita K, Fuchimoto S, Tanaka N, Ogawa N. The prognostic advantage of preoperative intratumoral injection of OK-432 for gastric cancer patients. Br J Cancer. 2001;84(4):443–51. doi:10.1054/bjoc.2000.1599.
   PubMed Web of Science ®Google Scholar
• Kasahara K, Shibata K, Shintani H, Iwasa K-I, Sone T, Kimura H, Nobata H, Hirose T, Yoshimi Y, Katayama N, et al. Randomized phase II trial of OK-432 in patients with malignant pleural effusion due to non-small cell lung cancer. Anticancer Res. 2006;26(2B):1495–99. PMID: 16619563.
   PubMed Web of Science ®Google Scholar
• Okamoto M, Furuichi S, Nishioka Y, Oshikawa T, Tano T, Ahmed SU, Takada K, Arita S, Ryoma Y, Moriya Y, et al. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation. Cancer Res. 2004;64(15):5461–70. doi:10.1158/0008-5472.CAN-03-4005.
   PubMed Web of Science ®Google Scholar
• Nagai K, Adachi T, Harada H, Eguchi S, Sugiyama H, Miyazaki Y. Dendritic cell-based immunotherapy pulsed with Wilms tumor 1 peptide and mucin 1 as an adjuvant therapy for pancreatic ductal adenocarcinoma after curative resection: a phase I/IIa clinical trial. Anticancer Res. 2020;40(10):5765–76. doi:10.21873/anticanres.14593.
   PubMed Web of Science ®Google Scholar
• Bilici A. Prognostic factors related with survival in patients with pancreatic adenocarcinoma. World J Gastroenterol. 2014;20(31):10802–12. doi:10.3748/wjg.v20.i31.10802.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Cheng S, Fathy AH, Qian H, Zhao Y. Prognostic value of platelet-to-lymphocyte ratio in pancreatic cancer: a comprehensive meta-analysis of 17 cohort studies. Onco Targets Ther. 2018;11:1899–908. doi:10.2147/OTT.S154162.
   PubMed Web of Science ®Google Scholar
• Tanaka A, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Cell Research. 2017;27(1):109–18. doi:10.1038/cr.2016.151.
   PubMed Web of Science ®Google Scholar
• Cheng H, LuoG, Lu Y, JinK, Guo M, XuJ, Kong J, LiuL, YuX, Liu C. The combination of systemic inflammation-based marker NLR and circulating regulatory T cells predicts the prognosis of resectable pancreatic cancer patients. Pancreatology. 2016;16(6):1080–84. doi:10.1016/j.pan.2016.09.007.
   PubMed Web of Science ®Google Scholar
• Tang Y, Xu X, Guo S, Zhang C, Tang Y, Tian Y, NiB, Lu B, Wang H. An increased abundance of tumor-infiltrating regulatory T cells is correlated with the progression and prognosis of pancreatic ductal adenocarcinoma. PLoS One. 2014;9(3):e91551. doi:10.1371/journal.pone.0091551.
   PubMed Web of Science ®Google Scholar
• Liu C, Cheng H, Luo G, Lu Y, Jin K, Guo M, Ni Q, Yu X. Circulating regulatory T cell subsets predict overall survival of patients with unresectable pancreatic cancer. Int J Oncol. 2017;51(2):686–94. doi:10.3892/ijo.2017.4032.
   PubMed Web of Science ®Google Scholar